Erratum to: Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants(Transgenic Res, 10.1007/s11248-010-9384-7);Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell xenografts

Transgenic Research

Volumn 19, Issue 6, 2010, Pages 1109-1117

  Izukuri, Kazuhito ^a   Suzuki, Kenji ^a   Yajima, Nobuyuki ^a   Ozawa, Shigeyuki ^a   Ito, Shin ^a   Kubota, Eiro ^a   Hata, Ryu Ichiro ^a  

^a KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

Chemokine CXCL14 BRAK; Lewis lung carcinoma cells; Transgenic mouse; Tumor suppression; Tumor therapy

Indexed keywords

MUS; MUS MUSCULUS;

EID: 78149471244     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-010-9436-z     Document Type: Erratum

References (40)

1. Akhurst RJ (2002) TGF-β antagonists: why suppress a tumor suppressor? J Clin Invest 109: 1533-1536.
2. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32.
3. Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A (2009) CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106: 3414-3419.
4. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68: 1-8.
5. Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C (2008) A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response. Nucleic Acids Res 36: 1415-1428.
6. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1: 46-54.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
8. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nature Med 14: 518-527.
9. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, Clayman GL (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156: 1937-1950.
10. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH (1980) Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci USA 77: 7380-7384.
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
12. Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K II, Azam M, Hou YH (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255: 703-706.
13. Izukuri K, Ito S, Nozaki N, Yajima N, Iwamiya M, Kawahara S, Suzuki K, Kubota E, Hata R (2010) Determination of serum BRAK/CXCL14 level in healthy volunteers. LabMedicine (in press).
14. Kakinuma T, Hwang ST (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79: 639-651.
15. Krieg C, Boyman O (2009) The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol 19: 76-83.
16. Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 194: 855-861.
17. Meuter S, Moser B (2008) Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cytokine 44: 248-255.
18. Nara N, Nakayama Y, Okamoto S, Tamura H, Kiyono M, Muraoka M, Tanaka K, Taya C, Shitara H, Ishii R, Yonekawa H, Minokoshi Y, Hara T (2007) Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem 282: 30794-30803.
19. Nishimura G, Yanoma S, Satake K, Ikeda Y, Taguchi T, Nakamura Y, Hirose F, Tsukuda M (2000) An experimental model of tumor dormancy therapy for advanced head and neck carcinoma. Jpn J Cancer Res 91: 1199-1203.
20. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
21. Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E, Hata R (2006) BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun 348: 406-412.
22. Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Kubota E, Hata RI (2009a) Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci 100: 2202-2209.
23. Ozawa S, Kato Y, Kubota E, Hata R (2009b) BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse. Biomed Res 30: 315-318.
24. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
25. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, Huang P (2009) Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res 69: 2375-2383.
26. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256: 137-165.
27. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3: 132-143.
28. Sato K, Ozawa S, Izukuri K, Kato Y, Hata R (2010) Expression of tumor-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro. Cell Biol Int (in press).
29. Schaerli P, Willimann K, Ebert LM, Walz A, Moser B (2005) Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23: 331-342.
30. Schwarze SR, Luo J, Isaacs WB, Jarrard DF (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64: 67-74.
31. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D, Clayman GL, Frederick MJ (2004) CXCL14/BRAK is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64: 8262-8270.
32. Sidransky D (2002) Emerging molecular markers of cancer. Nat Rev Cancer 2: 210-219.
33. Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, Hromas R (2006) The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 34: 1101-1105.
34. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafel AB (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270: 27348-27357.
35. Suzuki K, Oida T, Hamada H, Hitotsumatsu O, Watanabe M, Hibi T, Yamamoto H, Kubota E, Kaminogawa S, Ishikawa H (2000) Gut cryptopatches: Direct evidence of extrathymic anatomical sites for intestinal T lymphopoiesis. Immunity 13: 691-702.
36. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
37. Wang JM, Deng X, Gong W, Su S (1998) Chemokines and their role in tumor growth and metastasis. J Immunol Methods 220: 1-17.
38. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Buchler MW, Friess H (2008) CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 259: 209-217.
39. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84: 9233-9237.
40. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7: 243.